Recent Advances in the Generation of Antibody–Nanomaterial Conjugates,Advanced Healthcare Materials

当前位置： X-MOL 学术 › Adv. Healthcare Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Recent Advances in the Generation of Antibody–Nanomaterial Conjugates
Advanced Healthcare Materials ( IF 10.0 ) Pub Date : 2017-09-29 , DOI: 10.1002/adhm.201700607
Amal J. Sivaram _{1,

2,

3} , Andri Wardiana ₁ , Christopher B. Howard _{1,

2,

4} , Stephen M. Mahler _{1,

4} , Kristofer J. Thurecht _{1,

2,

3}

Affiliation

Targeted nanomedicines have significantly changed the way new therapeutics are designed to treat disease. Central to successful therapeutics is the ability to control the dynamics of protein–nanomaterial interactions to enhance the therapeutic effect of the nanomedicine. The aim of this review is to illustrate the diversity and versatility of the conjugation approaches involved in the synthesis of antibody–nanoparticle conjugates, and highlight significant new advances in the field of bioconjugation. Such nanomedicines have found utility as both advanced therapeutic agents, as well as more complex imaging contrast agents that can provide both anatomical and functional information of diseased tissue. While such conjugates show significant promise as next generation targeted nanomedicines, it is recognized that there are in fact no clinically approved targeted therapeutics on the market. This fact is reflected upon within this review, and attempts are made to draw some reasoning from the complexities associated with the bioconjugation chemistry approaches that are typically utilized. Present trends, as well as future directions of next generation targeted nanomedicines are also discussed.

中文翻译：

抗体-纳米材料共轭物的产生的最新进展

靶向纳米药物已经大大改变了设计新疗法治疗疾病的方式。成功的治疗方法的核心是控制蛋白质与纳米材料相互作用的动力学以增强纳米药物治疗效果的能力。这篇综述的目的是说明抗体-纳米颗粒偶联物合成中涉及的偶联方法的多样性和多功能性，并重点介绍生物偶联领域的重大新进展。已经发现这样的纳米药物既可用作先进的治疗剂，又可用作可提供患病组织的解剖学和功能信息的更复杂的成像造影剂。尽管这类偶联物有望成为下一代靶向纳米药物，公认的是，实际上市场上没有临床认可的靶向治疗剂。这一事实在本综述中得到了反映，并尝试从与通常使用的生物共轭化学方法相关的复杂性中得出一些推理。还讨论了下一代靶向纳米药物的当前趋势以及未来方向。

更新日期：2017-09-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11